Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries

Published:2024-02-28 Issue:3 Volume:30 Page:575-576
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Mannucci Pier Mannuccio¹^ORCID,Hermans Cedric²

Affiliation:

1. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

2. Division of Haematology, Haemostasis and Thrombosis Unit, Saint‐Luc University Hospital Université Catholique de Louvain (UCLouvain) Brussels Belgium

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14968

Reference11 articles.

1. Emicizumab state‐of‐the‐art update

2. Emicizumab: the hemophilia A game changer

3. Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)

4. The 50 best‐selling pharmaceuticals of 2022: cOVID‐19 vaccines poised to take a step back;Buntz B;Drug Discov Dev

5. WFH Humanitarian Aid Program impact report 2022. Last access December 2023.https://wfh.org/article/wfh‐humanitarian‐aid‐program‐impact‐report‐2022‐released/

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pros and cons of the ISTH treatment guidelines for hemophilia;Journal of Thrombosis and Haemostasis;2024-09

2. Emicizumab plasma levels after accelerated saturation in acquired haemophilia A;Haemophilia;2024-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP